Evercore ISI analyst Daniel Markowitz raised the firm’s price target on West Pharmaceutical (WST) to $390 from $350 and keeps an Outperform rating on the shares. On the company’s earnings call, management “sounded good and communicated comfort” with current Street estimates for 2026, notes the analyst, who sees a “strong setup into 2026 with upside potential.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- Early notable gainers among liquid option names on October 23rd
- Strong Q3 Performance and Raised 2025 Guidance Justify Buy Rating for West Pharmaceutical Services
- West Pharmaceutical Services Reports Strong Q3 2025 Results
- West Pharmaceutical ups FY25 adjusted EPS view to $7.06-$7.11 from $6.65-$6.85
- West Pharmaceutical reports Q3 adjusted EPS $1.96, consensus $1.69